Platelet (dys)function and plasma plasminogen levels in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 2, 2008, Pages 133-136

  Salobir, Barbara ^a   Sabovic, Miso ^a   Zupan, Irena Preloznik ^a   Ponikvar, Jadranka Buturovic ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

D dimer; Fibrinogen; Fibrinolysis; Hemodialysis; Plasminogen; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; D DIMER; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; BLOOD PLATELETS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PROTHROMBIN; RENAL DIALYSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 41749105069     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00558.x     Document Type: Article

References (26)

1. Deykin D. Uremic bleeding. Kidney Int 1983 24 : 698 705.
2. Remuzzi G. Bleeding in renal failure. Lancet 1988 1 : 1205 8.
3. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994 23 : 828 35.
4. Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991 64 : 81 90.
5. Sagripanti A, Cupisti A, Baicchi U, Ferderghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993 63 : 273 8.
6. Irish A. Cardiovascular disease, fibrinogen and acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998 137 : 133 9.
7. Brommer EJP, Schicht I, Wijngaards G, Verheijen JH, Rijken DC. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemost 1984 52 : 311 14.
8. Nakamura Y, Chida Y, Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nephron 1991 58 : 201 4.
9. Hong Sy Yang DH. Insulin levels and fibrinolytic activity in patients with end-stage renal disease. Nephron 1994 68 : 329 33.
10. Gris J-C, Ranger B, Vecina F, Sabadini BA, Fourcade J, Schved J-F. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994 46 : 807 13.
11. Takagi M, Wada H, Mukai K et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinolysis 1994 5 : 713 17.
12. Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997 46 : 36 40.
13. De Marchi S, Cecchin E, Falleti E et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997 8 : 1147 56.
14. Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 1996 83 : 351 61.
15. Gordge MP, Faint RW, Rylance FB, Ireland H. Lane DA, Neild GH. Plasma D dimer: a useful marker of fibrin breakdown in renal failure. Thromb Haemostas 1989 61 : 522 5.
16. Gordge MP, Neild GH. Platelet function in uremia. Platelets 1991 2 : 115 23.
17. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004 30 : 579 89.
18. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006 19 : 317 22.
19. Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 1999 56 : 299 305.
20. Adelman B, Michelson AD, Greenberg J, Handin RI. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood 1996 68 : 1280 4.
21. Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994 83 : 404 14.
22. Mezzano D, Panes O, Munoz B, et al. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure. Thromb Haemost 1999 82 : 1250 4.
23. Mezzano D, Tagle R, Panes O et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996 76 : 312 21.
24. Vujkovac B, Lavre J, Sabovic M. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient. Am J Kidney Dis 1998 31 : 536 8.
25. Vujkovac B, Sabovic M. Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid. Nephrol Dial Transplant 2000 15 : 107 9.
26. Sabovic M, Lavre J, Vujkovac B. Tranexamic acid is beneficial as adjunctive therapy in treatment of major upper gastrointestinal bleeding in dialysis patients. Nephrol Dial Transplant 2003 18 : 1 4.